Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1137–1143. doi: 10.1128/aac.33.8.1137

Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.

A DeMaria Jr 1, T L Treadwell 1, C A Saunders 1, R Porat 1, W R McCabe 1
PMCID: PMC172614  PMID: 2679368

Abstract

Aztreonam was compared with aminoglycoside antibiotics (tobramycin and amikacin) in a randomized, prospective, clinical trial in serious infections caused by gram-negative bacilli (GNB). A total of 43 evaluable patients with 47 infected sites were treated with aztreonam, and 41 evaluable patients were treated with aminoglycosides for 43 infections. Of patients treated with aztreonam, 17 were bacteremic, as were 12 of those treated with aminoglycosides. Clinical and microbiologic response rates were similar, except that only 5 of 11 patients with pneumonia were considered to be clinically cured with aminoglycoside therapy, while 5 of 6 patients with pneumonia treated with aztreonam were cured. Renal impairment was observed in 9 of 54 patients who received aminoglycoside antibiotics, but in only 2 of 53 patients treated with aztreonam. Hearing impairment developed in one patient treated with tobramycin. Transient elevations of serum transaminase levels occurred in 9 of 53 patients treated with aztreonam and in only 2 of 54 aminoglycoside-treated patients. Diarrhea and superinfection occurred with equal frequency in both groups. Serum concentrations of bactericidal activity could not be correlated with the outcome of therapy. Aztreonam appears to have comparable clinical efficacy with aminoglycoside antibiotics for the treatment of serious infections caused by aerobic and facultative GNB. Its use as a single agent for the treatment of serious lower respiratory infections caused by GNB warrants further evaluation.

Full text

PDF
1137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adkinson N. F., Jr, Saxon A., Spence M. R., Swabb E. A. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S613–S621. doi: 10.1093/clinids/7.supplement_4.s613. [DOI] [PubMed] [Google Scholar]
  2. Greenberg R. N., Reilly P. M., Luppen K. L., McMillian R., Bollinger M., Wolk S. M., Darji T. B., Noorani A. A. Treatment of serious gram-negative infections with aztreonam. J Infect Dis. 1984 Nov;150(5):623–630. doi: 10.1093/infdis/150.5.623. [DOI] [PubMed] [Google Scholar]
  3. Henry S. A., Bendush C. B. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Am J Med. 1985 Feb 8;78(2A):57–64. doi: 10.1016/0002-9343(85)90206-2. [DOI] [PubMed] [Google Scholar]
  4. Lerner A. M. The gram-negative bacillary pneumonias. Dis Mon. 1980 Nov;27(2):1–56. doi: 10.1016/s0011-5029(80)80015-0. [DOI] [PubMed] [Google Scholar]
  5. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  6. Neu H. C., Labthavikul P. Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):111–122. doi: 10.1093/jac/8.suppl_e.111. [DOI] [PubMed] [Google Scholar]
  7. Newman T. J., Dreslinski G. R., Tadros S. S. Safety profile of aztreonam in clinical trials. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S648–S655. doi: 10.1093/clinids/7.supplement_4.s648. [DOI] [PubMed] [Google Scholar]
  8. Nolen T. M., Phillips H. L., Hall H. J. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S666–S668. doi: 10.1093/clinids/7.supplement_4.s666. [DOI] [PubMed] [Google Scholar]
  9. Rodriguez J. R., Ramirez-Ronda C. H. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections. Am J Med. 1985 Feb 8;78(2A):42–43. doi: 10.1016/0002-9343(85)90202-5. [DOI] [PubMed] [Google Scholar]
  10. Sabath L. D., Casey J. I., Ruch P. A., Stumpf L. L., Finland M. Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma. J Lab Clin Med. 1971 Sep;78(3):457–463. [PubMed] [Google Scholar]
  11. Schentag J. J., Vari A. J., Winslade N. E., Swanson D. J., Smith I. L., Simons G. W., Vigano A. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med. 1985 Feb 8;78(2A):34–41. doi: 10.1016/0002-9343(85)90201-3. [DOI] [PubMed] [Google Scholar]
  12. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  13. Scully B. E., Neu H. C. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med. 1985 Feb;78(2):251–261. doi: 10.1016/0002-9343(85)90435-8. [DOI] [PubMed] [Google Scholar]
  14. Stratton C. W., Reller L. B. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. J Infect Dis. 1977 Aug;136(2):187–195. doi: 10.1093/infdis/136.2.187. [DOI] [PubMed] [Google Scholar]
  15. Swabb E. A. Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Am J Med. 1985 Feb 8;78(2A):11–18. doi: 10.1016/0002-9343(85)90197-4. [DOI] [PubMed] [Google Scholar]
  16. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  17. Weinstein M. P., Stratton C. W., Hawley H. B., Ackley A., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med. 1987 Aug;83(2):218–222. doi: 10.1016/0002-9343(87)90688-7. [DOI] [PubMed] [Google Scholar]
  18. Wolfson J. S., Swartz M. N. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. doi: 10.1056/NEJM198504113121507. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES